All In Biotech

Drug Trial Radar · NCT06222892

A Study of Camlipixant in Male and Female Healthy Participants and Participants With Hepatic Impairment Aged 18-75 Years of Age

A Phase 1, Open-label Study to Investigate the Pharmacokinetics and Safety of Camlipixant in Male and Female Participants Aged 18-75 Years of Age With Hepatic Impairment Compared to Matched Healthy Participants With Normal Hepatic Function

Last checked: Nov 20, 2026Latest source record: Jan 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

32

Actual

Start

Feb 2, 2024

Primary completion

Dec 17, 2024

Study completion Dec 30, 2024

Sponsor

Sponsor type
Industry
First posted
Jan 25, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the effect of Hepatic impairment (HI) on the Pharmacokinetic (PK) profile and safety of Camlipixant.

Conditions

  • Cough

Interventions

  • CamlipixantDrug

    Camlipixant was administered.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Area Under the Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC[0-inf]) of CamlipixantTime frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72 and 96 hours post-dose
  2. Part 2: AUC(0-inf) of CamlipixantTime frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72 and 96 hours post-dose
  3. Part 1: Maximum Observed Plasma Concentration (Cmax) of CamlipixantTime frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72 and 96 hours post-dose
  4. Part 2: Cmax of CamlipixantTime frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72 and 96 hours post-dose

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Miami, Florida

  • GSK Investigational Site

    Orlando, Florida

  • GSK Investigational Site

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.